Technical Topics

(TT005) Brazilian Multicenter Comparative Study to Characterize the Analytical Sensitivity and Expert’s Concordance, using Target-directed Sequencing of FFPE Samples

(TT006) A Multiplex RT-qPCR Assay for Mutation Detection and Measurable Residual Disease Monitoring in Acute Myeloid Leukemia

(TT007) QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection.

(TT008) Assessment of stability and alternative specimen sources for the clinical validation of a sample-to-answer BCR::ABL p190 assay in a low-prevalence setting

(TT009) Detection of Clinically Relevant Results in Specimens Failing to Pass Quality Control

(TT010) OptiMap: Precision Tumor Mapping Algorithm for Solid Tumor Molecular Testing

(TT011) ONT PromethION Adaptive Sampling Enables Improved Coverage of Clinically Relevant ‘Dark’ Genomic Regions Including the SMN1/2 Locus for Enhanced Variant Detection

(TT012) Validation of QuantStudio 3D Digital PCR Assay for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia

(TT013) Variant Calling Behind Threshold Lines: Lowering Levels of Detection Through Precise Error Modeling

(TT014) Analytical Validation (Accuracy, Reproducibility, Limit of Detection) of Foundation One RNA Assay For Fusion Detection In 189 Clinical Tumor Specimens

(TT015) NEBNext E5hmC-seq enables direct detection of 5-hydroxymethylcytosine at single base resolution

(TT016) Augmenting Screening of Histopathological Images for Breast Tumor Classification with Machine Learning and Limited Labeled Data

(TT017) Development of Clinical Laboratory Workflows for Liquid Biopsies and Molecular Analysis Including a Novel Automated Circulating Tumor Cell Enrichment System

(TT018) Automated, High Purity Isolation of Exosomes Using Alternating Current Electrokinetics Empowers Research and Diagnostics

(TT019) NPM1 Quantitation for AML Residual Disease Using ddPCR

(TT020) Performance of Copy Number Variant Detection from Short-Read Whole Genome Sequencing for Clinical Gene-Panel Applications

(TT021) Positive enrichment of Circulating tumor cells (CTCs) on the Kingfisher Purification System

(TT022) Development and Analytical Validation of nCounter-Platform Assay to Stratify Colorectal Cancer (CRC) into Consensus Molecular Subtype

(TT023) Expanding the scope of an existing custom-designed AmpliSeq oncology panel using a spike-in approach: a single institution’s experience

(TT024) Optimization of Fixed Solid Tumor Sample Preparation in RNase free Environment for RNA-based CLIA Assays

(TT025) NSG Library Quantification Standardization to Optimize Comprehensive Molecular Profiling in Hematologic Malignancy

(TT026) Assessment of Genomic Scars Using NxClinical 6.2 Results in the Identification of Homologous Recombination Deficient Tumors in a Pediatric Cancer Cohort

(TT027) Utilizing Hi-C Sequencing Analysis for Gene Rearrangement Detection in Neoplasms

(TT028) Assessment of Homologous Recombination DNA Repair Deficiency (HRD) score generation using copy number profiling data from targeted NGS compared to chromosomal microarray

(TT029) Incorporation of Parameters to Corroborate Variant Calling by a Proprietary Algorithm for an IDH1/2 PCR Assay

(TT030) Clinical Laboratory Experience of a Single Center Using ChimerMarker software for Automated Chimerism Genotyping Analysis and Monitoring

(TT031) MMSNP: A Novel Tool for Sample Cross-contamination Detection in Cell Free DNA Sequencing

(TT032) Creation of a Robust Control for Use in Cell Free DNA Sequencing

(TT033) Clinical Validation of an Automated Library Preparation Method for the TruSight Oncology 500 Assay Shows Improved Coverage of Clinically Relevant GC-Rich Regions

(TT034) Impact of Clinical Sample Formalin Fixation Duration on NGS RNA Sequencing Quality Metrics

(TT035) Quality Control of a New Probe Lot for a Laboratory Developed Hybrid Capture NGS Assay

(TT036) Technical Considerations and Challenges of Validating a Clinical Anchored Multiplex NGS-Based Assay for Known and Novel Fusion Detection in Cancer

(TT037) Unraveling the Link Between Total cfDNA Quantified by Agilent Cell-free DNA ScreenTape Assay and Actionable cfDNA Molecules Measured on Downstream Assays

(TT038) Effect of Heated EDTA Decalcification on Quality and Quantity of DNA for Molecular Testing

(TT039) Functional RNA Quantification: An effective Predictor of RNA Sequencing Success

(TT040) Multi-site performance of highly multiplexed next generation liquid biopsy reference material

(TT041) Improved SNV and InDel detection in an Exome NGS assay with novel Features

(TT042) Automated Purification for Robust Sample Performance on Ion Torrent Genexus System for Detection and Research of Myeloid Malignancies

(TT043) Assessment of the Cell-free DNA (cfDNA) Extraction using nRichDX® Revolution Sample Prep System from Plasma, Urine, and Pancreatic Cyst Fluid

(TT044) Rapid and Accurate Quantification of Endonuclease Activity Using a Kinetic FRET Assay

(TT045) Performance Evaluation of a Novel Multi-variant CFTR DNA Control

(TT046) Evaluation of MGMT methylation profiling in Glioblastoma clinical samples using MS-MLPA assay.

(TT047) Validation of a Quantitative RT-qPCR Assay for NPM1 Mutation Detection in Clinical Laboratory

(TT048) Reducing Thermocycler Ramp Rate Improves Coverage of GC-rich Regions in the Illumina TruSight Oncology 500 Assay

(TT049) Multiple Consecutive Quality Checkpoints Significantly Improve the Value of Biobanked Samples for Research

(TT050) Clinical Evaluation of the SJPedPanel Targeted Sequencing Assay: Optimization of Bioinformatics Processes Improves True Variant Detection and Operational Efficiency

(TT051) Combining High-Throughput, High-Resolution Targeted Spatial Microdissection with SLIMamp® NGS Chemistry for Sensitive and Accurate Molecular Characterization on Low-Quantity, Low-Quality FFPE Samples

(TT052) Bisulfite Conversion DNA Recovery Rate by Droplet Digital Polymerase Chain Reaction

(TT053) Tissue prior the initial H&E section as alternative source of DNA for molecular diagnostics

(TT054) Developing an Ultra-Rapid Extraction Technique for Intra-Operative Diagnosis and Tumor Margin Assessment

(TT055) Fourier Ptychography Microscopy: Physics-Driven Models for an Easier Path to Regulated Histopathology

(TT056) Optimizing Interpretive Criteria for Clonality Assessment in T-Cell Receptor Gamma Gene Rearrangement Studies by Next-Generation Sequencing

(TT057) Homologous Recombination Deficiency (HRD) Phenotype Assessment using Chromosomal Microarray (CMA) and 523-gene Next-Generation Sequencing (NGS) Panel: A comparative analysis

(TT058) Evaluation of Hi-C Sequencing as a Novel Diagnostic Technology for Detecting Genomic and Chromosomal Structural Variants in Constitutional Disorders

(TT059) Evaluation of Two Workflows for Variant Detection in Cell-Free DNA

(TT060) Fast and robust KMT2A copy number characterisation in a panel of AML cell lines using MLPA and digitalMLPA

(TT061) Development and Evaluation of Total RNA Sequencing Quality Controls for Blood-Based Biomarker Discovery

(TT062) Optical genome mapping as next generation cytogenomic technique in Clinical Laboratory: A 1000 sample experience.

(TT063) Replacing External Reference Materials with Internal Standards for Next Generation Sequencing

(TT064) Ultrasonicator Evaluation for TruSight Oncology 500 and Related Assays

(TT065) Mitochondrial DNA as an Intrinsic Control for Enhancing MSRE-Dependent DNA Methylation Analysis in Liquid Biopsy Diagnostics for Cancer

(TT066) Melanin-Bleaching for Biocartis Idylla BRAF Mutation Assay for Pigmented Melanoma

(TT067) A Targeted High-Throughput Next-Generation Sequencing Assay for Clinical Screening of Gene Fusions in Leukemias

(TT068) Pre-Analytic Variables and Quality Controls for Robust Processing of Plasma-Derived Cell-Free DNA (cfDNA) Using a Whole Methylome Enrichment Platform

(TT069) RNAmp: Detecting Gene Amplification Events Using Clinical RNA-Seq

(TT070) Exploring the Utility of NxClincal Software in Investigating Copy Number Alterations (CVA) in Myeloid Cancers Potential on Next Generation Sequencing (NGS): A Potential Game Changer.